Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment-Reference-Cited by-同舟云学术

Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment

Published:2019-08-05 Issue:11 Volume:19 Page:1127-1134
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

le Besnerais Maëlle¹²,Veyradier Agnès³⁴,Benhamou Ygal¹²,Coppo Paul⁴⁵

Affiliation:

1. Département de Médecine Interne, CHU Charles Nicolle, Rouen, France

2. Normandie Univ, UNIROUEN, INSERM U1096 EnVI, Rouen, France

3. Service d’Hématologie biologique and EA3518 Université Paris Diderot, Groupe Hospitalier Saint Louis – Lariboisière, Assistance Publique, Hôpitaux de Paris, Paris, France

4. French Reference Center for Thrombotic Microangiopathies, Hôpital Saint Antoine, Assistance Publique –Hôpitaux de Paris, Paris, France

5. Département d’Hématologie clinique, Paris, France

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1650908

Reference45 articles.

1. Thrombotic thrombocytopenic purpura

2. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy

3. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

4. Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification

5. Pathophysiology of thrombotic thrombocytopenic purpura

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanobody‐Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING‐Mediated Anti‐Tumor Immunity;Advanced Science;2024-06-18

2. Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab;BioDrugs;2024-04-08

3. Changes in inflammatory responses and autophagy during apheresis platelet preservation and its correlation with platelet transfusion refractoriness in patients with acute lymphoblastic leukemia;Biomolecules and Biomedicine;2023-07-04

4. Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis;Expert Opinion on Biological Therapy;2023-07-03

5. Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia;International Journal of Technology Assessment in Health Care;2023